1. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large B-cell lymphoma;Coiffier;N Engl J Med,2002
2. Ifosfamide, carboplatin, and etoposide: a highly effective cytoreduction and peripheral-blood progenitor-cell mobilization regimen for transplant-eligible patients with non-Hodgkin’s lymphoma;Moskowitz;J Clin Oncol,1999
3. Two-weekly CHOP (CHOP-14): the new standard regimen for patients with aggressive non-Hodgkin’s lymphoma (NHL) >60 years of age;Pfreundschuh;Ann Oncol,2002
4. The age-adjusted international prognostic index (AAIPI) predicts outcome following autologous stem cell transplantation (ASCT) in patients (PTS) with relapsed and primary refractory diffuse large B-cell lymphoma (DLBCL);Hamlin;Ann Oncol,2002
5. Rituximab significantly increases the complete response rate in patients with relapsed or primary refractory DLBCL receiving ICE as second-line therapy (SLT);Kewalramani,2001